Genetix Biotherapeutics
PublicGenetix Biotherapeutics is now publicly traded
The data on this page reflects Genetix Biotherapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jun 19, 2013
Last Round
Buyout/LBO
Jun 2, 2025
Est. Valuation at Exit
$45M
Total Funding Raised
$1.85B
Company Overview
Genetix Biotherapeutics is a biotechnology company that researches, develops, and commercializes potentially transformative gene therapies for severe genetic diseases.
AI Layer
Non-AI
Keywords
Genetix Biotherapeutics Comparables
Compare Genetix Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Jaguar Gene Therapy | 64% | |
| Frontera Therapeutics | 64% | |
| EdiGene | 62% |
Genetix Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Buyout/LBO | Jun 2, 2025 | ||||
| Debt | Mar 18, 2024 | ||||
| Follow-on Offering | Dec 19, 2023 | ||||
| Private Placement | Jun 3, 2022 | ||||
| Private Placement | Sep 8, 2021 | ||||
Follow-on Offering | May 18, 2020 |
Genetix Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hercules Capital | Debt |
| Forbion Capital Partners | Series D, Series C, Series A |
| RA Capital Management | Series D |
| BofA Securities | Follow-on Offering |
| ARCH Venture Partners | Series D, Series C |
| California Institute for Regenerative Medicine | Grant |
| Raymond James | Follow-on Offering |
Genetix Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access